What is DoseMe?
DoseMe operates within the healthcare technology sector, developing sophisticated clinical software solutions aimed at optimizing medication dosing for individual patients. The company's core focus is on leveraging advanced pharmacokinetic and pharmacodynamic modeling, combined with patient-specific clinical data, to assist healthcare professionals in determining the most appropriate drug dosages. This approach enhances medication safety and treatment efficacy within hospital and pharmacy settings. Their flagship platform, DoseMeRx, provides model-informed precision dosing, moving beyond traditional standardized guidelines to offer personalized therapeutic recommendations based on a comprehensive analysis of patient characteristics, laboratory results, and drug concentrations.
How much funding has DoseMe raised?
DoseMe has raised a total of $3.1M across 2 funding rounds:
Angel/Seed
$500K
Series A
$2.6M
Angel/Seed (2014): $500K, investors not publicly disclosed
Series A (2016): $2.6M, investors not publicly disclosed
What's next for DoseMe?
With a recent major strategic investment and substantial total funding, DoseMe is poised for accelerated scaling and further development of its precision dosing technology. This capital infusion is expected to fuel expansion into new markets, enhance the capabilities of the DoseMeRx platform, and strengthen its position as a leader in evidence-based clinical decision support. The company's focus on improving patient outcomes through data-driven insights suggests a continued emphasis on research and development, potentially leading to broader applications of its modeling technology across various therapeutic areas and healthcare systems.
See full DoseMe company page
